SANDOZ' ORAL ANTIALLERGIC ZADITEN (KETOTIFEN) IS A JAPANESE MARKET LEADER IN ASTHMA WITH ANNUAL SALES AT $60 MIL.: U.S., APPROVAL COULD BE NEAR, SRI SAYS

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".